- •Contents
- •Foreword
- •Preface
- •List of Abbreviations
- •1. General Topics in Ophthalmology
- •Approach to the Patient: Exam and History
- •Embryology and Development
- •Emergencies
- •Epidemiology/Statistics
- •Genetics
- •Imaging: Computed Tomography (CT)
- •Imaging: Magnetic Resonance Imaging (MRI)
- •Optics
- •Pathology
- •Pregnancy
- •Radiation/Laser
- •Surgery
- •2. Orbit, Eyelids, and Ocular Adnexa
- •Anatomy and Physiology
- •Signs and Symptoms
- •Exam and Imaging
- •Congenital and Genetic Disease
- •Infectious Disease
- •Neoplastic, Eyelid: Benign Cystic Lesions
- •Neoplastic, Eyelid: Benign Growths
- •Neoplastic, Eyelid: Hair Follicle Tumors (‘‘Tricky’’ Tumors)
- •Neoplastic, Eyelid: Premalignant Lesions
- •Neoplastic, Eyelid: Malignant Lesions
- •Neoplastic, Eyelid and Orbital: Pigmented Lesions
- •Neoplastic, Orbital: Lacrimal Gland Tumors
- •Neoplastic, Orbital: Lymphoproliferative Lesions
- •Neoplastic, Orbital: Mesenchymal Tumors
- •Neoplastic, Orbital: Metastatic and Invasive Tumors
- •Neoplastic, Orbital: Neurogenic Tumors
- •Neoplastic, Orbital: Structural Lesions
- •Neoplastic, Orbital: Vascular Lesions
- •Metabolic and Degenerative Disease
- •Systemic and Vascular Disease
- •Physical Disease
- •Inflammatory and Immune Disease
- •Eyelid Surgery
- •Lacrimal Surgery
- •Orbital Surgery
- •Other Surgery
- •3. Cornea and Conjunctiva
- •Anatomy and Physiology
- •Signs and Symptoms
- •Exam and Imaging
- •Congenital and Genetic Disease
- •Infectious Disease
- •Neoplastic Disease: Benign Masses
- •Neoplastic: Malignant
- •Neoplastic: Melanocytic Lesions
- •Metabolic and Degenerative Disease
- •Physical Disease
- •Inflammatory and Immune Disease
- •Surgery
- •4. Glaucoma
- •Anatomy and Physiology
- •Signs and Symptoms
- •Exam and Imaging
- •Infantile and Pediatric Glaucoma
- •Primary Open-Angle Glaucoma
- •Secondary Open-Angle Glaucomas
- •Primary Angle-Closure Glaucoma
- •Secondary Angle-Closure Glaucoma
- •Surgery
- •Iris
- •Uveitis
- •Signs and Symptoms and Clinical Presentations of Uveitis
- •Anterior Uveitis Diagnosis and Work-Up
- •Anterior Uveitis Diseases
- •Intermediate Uveitis Diagnosis and Work-Up
- •Intermediate Uveitis Diseases
- •Posterior Uveitis Diagnosis and Work-Up
- •Posterior Uveitis Diseases
- •Panuveitis/Diffuse Uveitis
- •Surgery
- •6. Lens
- •Anatomy and Physiology
- •Signs and Symptoms
- •Congenital and Genetic Disease
- •Metabolic and Degenerative Disease
- •Systemic and Vascular Disease
- •Physical Disease
- •Cataract Surgery
- •Refractive Lens Surgery
- •7. Retina and Vitreous
- •Anatomy and Physiology
- •Signs and Symptoms
- •Exam and Imaging
- •Congenital and Genetic Disease
- •Hereditary Macular Disorders
- •Progressive Tapetoretinal Disorders
- •Stationary Tapetoretinal Disorders
- •Congenital and Genetic Vitreoretinopathies
- •Infectious Disease
- •Infectious Endophthalmitis
- •Neoplastic Disease
- •Metabolic and Degenerative Disease
- •Systemic and Vascular Disease
- •Physical Disease
- •Surgery: Laser
- •Surgery: Operative
- •8. Neurologic
- •Anatomy and Physiology
- •Signs and Symptoms
- •Exam and Imaging
- •Congenital and Genetic Disease
- •Infectious Disease
- •Neoplastic Disease
- •Metabolic and Degenerative Disease
- •Systemic and Vascular Disease
- •Physical Disease
- •Inflammatory and Immune Disease
- •Selected Cranial Nerve Abnormalities
- •Gaze Abnormalities
- •Nystagmus
- •Psychiatric Diseases
- •9. Pediatrics and Strabismus
- •Anatomy and Physiology
- •Signs and Symptoms
- •Exam and Imaging
- •Congenital and Genetic Disease
- •Congenital Disease: Phakomatoses
- •Strabismus: Esotropia
- •Strabismus: Exotropia
- •Strabismus: Vertical Deviations
- •Surgery
- •Other
- •10. Medications
- •General
- •Antibacterials: Aminoglycosides
- •Antibacterials: Cephalosporins and Penicillins
- •Antibacterials: Fluoroquinolones
- •Antibacterials: Inhibitors of Cell Wall Function
- •Antibacterials: Inhibitors of Nucleic Acid Synthesis
- •Antibacterials: Inhibitors of Protein Synthesis
- •Antibacterials: Combinations
- •Antibacterial and Corticosteroid Combinations
- •Antifungal Agents
- •Anti-inflammatory: Allergy
- •Anti-inflammatory: Nonsteroidals
- •Antiseptics
- •Antiviral Agents
- •Glaucoma: Beta-Blockers
- •Glaucoma: Carbonic Anhydrase Inhibitors
- •Glaucoma: Hyperosmotics
- •Glaucoma: Miotics/Cholinergic, Direct Acting
- •Glaucoma: Miotics/Cholinergic, Indirect Irreversible
- •Glaucoma: Prostaglandin Analogues
- •Glaucoma: Sympathomimetics
- •Immunosuppressives: Antimetabolites
- •Immunosuppressives: Alkylating Agents
- •Immunosuppressives: Noncytotoxic
- •Miotics: Cholinergic, Indirect Reversible
- •Mydriatics and Cycloplegics: Anticholinergic
- •Mydriatics: Adrenergic
- •Neurologic Medications
- •Other Agents
- •Index
CHAPTER 10
Medications
General
PHARMACOKINETICS Average drop ¼ 50 mL; however, the tear lake holds only 10 mL. Tear turnover is 16% per minute; thus, approximately 50% remains at 4 minutes. Most drops act by Þrst-order kinetics: a constant fraction is absorbed and eliminated (e.g., 100 ! 50 ! 25 ! 12.5, etc.).
DRUG PERMEABILITY Penetration into the eye is dependent on
Lipid solubility: characterized by the partition coefÞcient; a higher coefÞcient indicates more lipid solubility and thus greater permeability. Partition coefÞcient ¼ (drug in lipid phase) (drug in aqueous phase).
Corneal permeability: cornea structure is soluble to fat (epithelial layer), then water (stroma), then fat (endothelial layer). Thus, the more lipid that is soluble, the greater the permeability, up to a point. Surfactants and increased concentration of the drug (up to the point of increased tearing) increase corneal permeability.
Ionization status: Henderson-Hasselbach equation demonstrates that a substance with higher pH is more nonionized or uncharged and is more lipid soluble.
Antibacterials: Aminoglycosides
PROPERTIES Bind 30S bacterial ribosomal subunit, irreversible and thus bactericidal. Active against many gram-negative and staphylococcal organisms.
AMIKACIN 20Ð50 mg/mL fortiÞed topical, 0.4 mg intravitreal.
GENTAMICIN (Garamycin) 1 drop every 4 hours or ½ inch ribbon of ointment bidÐtid (solution 0.3%, ointment 0.3%).
NEOMYCIN SigniÞcant topical hypersensitivity.
TOBRAMYCIN (Tobrex) 1 drop every l to 4 hours or ½ inch ribbon of ointment every 3 to 4 hours or bidÐtid (solution 0.3%, ointment 0.3%), or
373
Goodman, Ophtho Notes © 2003 Thieme
All rights reserved. Usage subject to terms and conditions of license.
374 MEDICATIONS
fortiÞed topical 14 mg/mL solution, 0.1Ð0.2 mg intravitreal. Slightly more active against Pseudomonas than gentamicin.
Antibacterials: Cephalosporins and Penicillins
PROPERTIES Beta-lactam antibiotics that inhibit bacterial transpeptization enzymes necessary for cell wall synthesis; bactericidal.
CEFAZOLIN (Ancef) 50 mg/mL fortiÞed topical solution or 100 mg subconjunctival injection. First-generation cephalosporin that is active against most gram-positive cocci.
CEFTAZIDIME 2.25 mg intravitreal. Third-generation cephalosporin with greater activity against gram-negative organisms, including Pseudomonas.
PENICILLIN G 200,000 units/mL fortiÞed topical, 1 million units subconjunctival, 2 million to 18 million units intravenous every 4 to 6 hours. Active against most streptococci, gonococci, and anaerobes. Most staphylococci produce beta-lactamase and are resistant. Hypersensitivity in 3 to 10%.
Antibacterials: Fluoroquinolones
PROPERTIES Inhibits bacterial DNA gyrase, thus interfering with DNA replication; bactericidal and inhibitory. Active against most gram-negative organisms, staphylococci, and many streptococci. Avoid ßuoroquinolones in children, as they may inhibit cartilage and growth plate development.
CIPROFLOXACIN (Ciloxan) ointment bidÐtid (solution ßuoroquinolone.
1 gtt every l to 6 hours or ½ inch ribbon 0.3%, ointment 0.3%). Second-generation
GATIFLOXACIN (Zymar) 1 gtt every 1 to 6 hours (solution 0.3%). Fourthgeneration ßuoroquinolone.
LEVOFLOXACIN (Levoquin, Quixin) 1 gtt every l to 6 hours (solution 0.5%). Third-generation ßuoroquinolone.
MOXIFLOXACIN (Vigamox) 1 gtt every 1 to 6 hours (solution 0.5%). Fourth-generation ßuoroquinolone.
NORFLOXACIN (Chibroxin) 1 drop every 2 to 6 hours (solution 0.3%).
OFLOXACIN (Ocuflox) 1 drop every l to 6 hours (solution 0.3%).
Goodman, Ophtho Notes © 2003 Thieme
All rights reserved. Usage subject to terms and conditions of license.
ANTIBACTERIALS: INHIBITORS OF PROTEIN SYNTHESIS |
375 |
Antibacterials: Inhibitors of Cell Wall Function
BACITRACIN Ointment every 3 to 4 hours or bidÐqid. Polypeptide that inhibits early steps in peptidoglycan synthesis. Treats Neisseria, H. flu, Actinomyces, and most gram-positive bacteria.
POLYMYXIN B AND GRAMICIDIN Detergent-like action to increase cytoplasmic membrane permeability. Polymyxin B is mixture of basic peptides that dissolve cell membranes with greatest activity against gram-negative bacteria.
VANCOMYCIN FortiÞed topical 50 mg/mL, 1 mg in 0.1 mL intravitreal, 2 g every 6 to 12 hours intravenous. Inhibits early steps in peptidoglycan synthesis. High level of activity against most gram-positive cocci and bacilli.
Antibacterials: Inhibitors of Nucleic Acid Synthesis
PYRIMETHAMINE Inhibits conversion of dihydrofolic acid into tetrahydrofolic acid, but also more active against host cell and thus more toxic than trimethoprim; bacteriostatic.
RIFAMPIN Binds to bacterial DNA-dependent RNA polymerase.
SULFACETAMIDE (Sulamyd, Bleph-10, Sulf-10, Isopto Cetamide) 1 drop every 2 to 6 hours (solution 10, 15, 30%) or ½ inch ribbon of ointment every 3 to 8 hours (ointment 10%). Bacteriostatic inhibition of folic acid synthesis by competing with PABA for conversion into dihydrofolic acid. Active against many gram-positive, gram-negative, Chlamydia, Actinomyes, and Nocardia organisms.
TRIMETHOPRIM Inhibits conversion of dihydrofolic acid into tetrahydrofolic acid; bacteriostatic.
Antibacterials: Inhibitors of Protein Synthesis
CHLORAMPHENICOL (Chloroptic) 1 drop every 4 to 6 hours (solution 0.5%), or small amount of ointment up to every 3 hours (ointment 1%), or make 5 mg/mL fortiÞed topical drops from 100 mg subconjunctival solution. Binds to the 50S ribosomal subunit; bacteriostatic. Active against many gram-positive, gram-negative, and anaerobic organisms. Idiosyncratic fatal aplastic anemia occurs with similar frequency to that of fatal anaphylaxis following penicillin therapy (about 1 in 50,000); also, can cause doserelated bone marrow suppression.
Goodman, Ophtho Notes © 2003 Thieme
All rights reserved. Usage subject to terms and conditions of license.
376 MEDICATIONS
CLINDAMYCIN 50 mg/mL fortiÞed topical. Binds the 50S subunit of bacterial ribosomes.
ERYTHROMYCIN (Ilotycin, AK-Mycin) ½ inch ribbon of ointment every 3 to 4 hours or bidÐqid (ointment 0.5%). Binds ribosomal 50S subunit. Similar activity to penicillin against gram-positive bacteria; also active against
Hemophilus, Neisseria, and Chlamydia.
TETRACYCLINE Binds 30S bacterial ribosomal subunit like aminoglycosides but has reversible binding and is thus bacteriostatic. Active against many gram-positive, gram-negative, Chlamydia, Actinomyes, and Mycobacterium organisms.
Antibacterials: Combinations
NEOSPORIN (neomycin þ bacitracin þ polymyxin B) 1 drop every l to 6 hours for 7 to 10 days or ½ inch ribbon of ointment every 3 to 4 hours for 7 to 10 days.
POLYSPORIN (polymyxin B + bacitracin) |
½ inch ribbon of ointment qid |
|
or every 3 to 4 hours for 7 to 10 days. |
|
|
POLYTRIM (polymyxin B þ trimethoprim) |
1 gtt every 3 to 6 hours for 7 to |
|
10 days, maximum 6 drops/day. |
|
|
Antibacterial and Corticosteroid Combinations |
|
|
CORTISPORIN (neomycin þ polymyxin þ hydrocortisone |
1%) 1 drop or |
|
½ inch ribbon of ointment every 3 to 4 hours. |
|
|
MAXITROL (dexamethasone þ neomycin þ polymyxin) |
1 drop every l to |
|
8 hours or ½Ð1 inch ribbon of ointment qdÐqid. |
|
|
TOBRADEX (tobramycin þ dexamethasone) 1 drop every 2 to 6 hours or
½ inch ribbon of ointment bidÐqid.
Antifungal Agents
AMPHOTERICIN B (AMB) 0.15% topical every 30 to 60 minutes initially for fungal corneal ulcers (mix AMB powder with sterile water), 5Ð10 mg intravitreal or 1 mg/kg/day intravenous for fungal endophthalmitis (limited by renal toxicity). Highly effective polyene antibiotic against a broad range of fungi.
Goodman, Ophtho Notes © 2003 Thieme
All rights reserved. Usage subject to terms and conditions of license.
